Evidence map›Paper›PMID 36832986›Full record

ArticleHealthcare (Basel, Switzerland)2023

Medication Adherence of People Living with HIV in Japan-A Cross-Sectional Study.

Yoji Inoue, Shinichi Oka, Seiji Yokoyama, Koichi Hasegawa, Jörg Mahlich, Ulrike Schaede, Noriyuki Habuka, Yoko Murata

Abstract read
In one paragraph

Article in Healthcare (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yoji InoueGraduate School of Health Care and Nursing, Juntendo University, Chiba 2790023, Japan.
Shinichi OkaAIDS Clinical Center, National Center for Global Health and Medicine, Tokyo 1628655, Japan.
Seiji YokoyamaMedical Affairs, Janssen Pharmaceutical K. K., Tokyo 1010065, Japan.
Koichi HasegawaMedical Affairs, Janssen Pharmaceutical K. K., Tokyo 1010065, Japan.ORCID 0000-0002-5200-8288
Jörg MahlichHealth Economics & Outcomes Research, Janssen-Cilag, 41470 Neuss, Germany.ORCID 0000-0003-1110-2793
Ulrike SchaedeSchool of Global Policy and Strategy, UC San Diego, La Jolla, CA 92093, USA.
Noriyuki HabukaMedical Affairs, Janssen Pharmaceutical K. K., Tokyo 1010065, Japan.
Yoko MurataMedical Affairs, Janssen Pharmaceutical K. K., Tokyo 1010065, Japan.ORCID 0000-0002-6512-3752

Funding

Janssen Pharmaceutical K. K. NA
6 · The paper itself

Abstract

Long-term medical care for people living with HIV (PLHIV) is critical for treatment efficacy, and various studies have examined reasons for antiretroviral therapy (ART) non-adherence. In Japan, doctors assume patients maintain high adherence. However, little is known about real-world treatment adherence. We conducted an anonymous self-administered web-based survey asking about adherence for a total of 1030 Japanese PLHIV who were currently on ART. Adherence was determined using the eight-item Morisky Medication Adherence Scale (MMAS-8), for which scoring ranged from 0 to 8 and scores < 6 points were classified as low adherence. Data were analyzed based on patient-related factors; therapy-related factors; condition-related factors, such as a comorbidity with depression (utilizing the Patient Health Questionnaire 9, PHQ-9); and healthcare/system-related factors. Among 821 PLHIV who responded to the survey, 291 responders (35%) were identified as being in the low adherence group. A statistically significant relationship was found between the number of missed anti-HIV drug doses within the previous 2 weeks and long-term adherence, per the MMAS-8 score (

Indexed as

adherenceJapanese PLHIVshared decision-making

Identifiers

PMID36832986
PMCPMC9957380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.